Imagine having type 2 diabetes and chronic kidney disease. You are already managing a complex health situation. Now, consider a specific measure of your kidney health called the KDIGO risk category. A recent look at data from a large trial found that patients taking finerenone were much more likely to see this category improve. Conversely, they were less likely to see it worsen compared to those taking a placebo.
The study looked at patients followed for 36 months. Those whose risk category improved had a reduced risk of a combined heart or blood vessel event. In contrast, those whose risk category worsened faced an increased risk of these serious outcomes. The numbers show a clear difference in how the risk category shifted between the two groups.
It is important to remember this was a post hoc subanalysis, meaning researchers looked at existing data after the main trial was done. While the link between these risk changes and heart events is strong, we must be careful not to say this proves the drug directly caused the heart benefits. Funding came from Bayer AG. These results are promising but need more direct study to confirm the full story.
